What will happen if i continue to use lexapro xanax and alprolazam and cafergot and darvacet?

Answer 1

Someone will need too write / read a eulogy at your funeral.

Answer 2

xanax and alprolazam(generic xanax) are the same drug ...for anxiety or panic disorder. Lexapro is also prescribed for the same as well as depression. Darvocet is a pain medication and I have no idea what cafergot is.
Long term effect...addiction with the xanax and darvocet,
these are not drugs to be taken lightly.
As far as the lexapro...it hasn't been on the market long enough to establish what the long term affects may or may not be.
Speak to your doctor and a pharmacist for more information

Answer 3

Well the cafergot is for GI disturbances which you probably have due to the other meds you take, but hey the good news is you should be so out of it you probably won't even know it hurts. See your Dr. or get a new one and get some help with your issues, please!!

Answer 4

Just because you feel well dose not mean you need to get off your meds, its means your meds are working and if the side effects are bothering you ask your doctor if they will go away, always ask your doctor before messing with your meds

Answer 5

darvocet...nothing
xanax..alprolazam same thing hard time sleeping or increase in anxiety

Never discontinue your medications without supervision from a doctor. You can have really bad side effects.

Answer 6

I've done a search for you to see what the interactions of all these drugs would be:

You have searched for drug interactions between the following
drugs: Lexapro, Xanax, Cafergot & darvocet (acetaminophen-propoxyphene)

Drug-Drug Interactions

alprazolam and acetaminophen-propoxyphene (major Drug-Drug)
Description:
MONITOR CLOSELY: Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. In a large Canadian study, propoxyphene use was also associated with a 60% increased risk of hip fracture in the elderly, and the risk was further increased by concomitant use of psychotropic agents (sedatives, antidepressants, neuroleptics), presumably due to additive psychomotor impairment. Therefore, these drugs may constitute a dangerous combination in certain susceptible populations. Pharmacokinetically, propoxyphene is a CYP450 2D6 inhibitor and may increase the plasma concentrations of many psychotropic agents such as neuroleptics (e.g., phenothiazines, haloperidol, risperidone), antidepressants (e.g., some tricyclic antidepressants and serotonin reuptake inhibitors), and phenobarbital.
MANAGEMENT:
Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.

acetaminophen-propoxyphene and propoxyphene (major Drug-Drug)
Description:
MONITOR CLOSELY: Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. In a large Canadian study, propoxyphene use was also associated with a 60% increased risk of hip fracture in the elderly, and the risk was further increased by concomitant use of psychotropic agents (sedatives, antidepressants, neuroleptics), presumably due to additive psychomotor impairment. Therefore, these drugs may constitute a dangerous combination in certain susceptible populations. Pharmacokinetically, propoxyphene is a CYP450 2D6 inhibitor and may increase the plasma concentrations of many psychotropic agents such as neuroleptics (e.g., phenothiazines, haloperidol, risperidone), antidepressants (e.g., some tricyclic antidepressants and serotonin reuptake inhibitors), and phenobarbital.

MANAGEMENT:
Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.

caffeine-ergotamine and ergotamine (major Drug-Drug)
Description:
MONITOR CLOSELY: Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and 5-hydroxytryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A receptors.

MANAGEMENT:
In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Close monitoring is recommended for signs and symptoms of excessive serotonergic activity such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia. Particular caution is advised when increasing the dosages of these agents. The potential risk of serotonin syndrome should be considered even when administering one serotonergic agent following discontinuation of another, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is recommended following use of fluoxetine before administering another serotonergic agent.

alprazolam and escitalopram (Lexapro) (moderate Drug-Drug)
Description:


MONITOR:
Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.

MANAGEMENT:
During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them. Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.



Drug-Food Interactions

caffeine-ergotamine (moderate Drug-Food)
Description:


MONITOR:
Grapefruit juice may increase the plasma concentrations of some orally administered drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. The extent and clinical significance are unknown. Moreover, pharmacokinetic alterations associated with interactions involving grapefruit juice are often subject to a high degree of interpatient variability.

MANAGEMENT:
Patients who regularly consume grapefruits and grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that are metabolized by CYP450 3A4. Grapefruits and grapefruit juice should be avoided if an interaction is suspected. Orange juice is not expected to interact with these drugs.

alprazolam (moderate Drug-Food)
Description:


GENERALLY AVOID:
The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice. The proposed mechanism is CYP450 3A4 enzyme inhibition.

MANAGEMENT:
The manufacturer recommends that grapefruit juice should not be taken with oral midazolam. Patients taking triazolam or alprazolam should be monitored for excessive sedation. Alternatively, the patient could consume orange juice which does not interact with these drugs.

caffeine-ergotamine (minor Drug-Food)
Description:


The effect of grapefruit juice on the pharmacologic activity of caffeine is controversial. One report suggests that grapefruit juice increases the effect of caffeine. The proposed mechanism is inhibition of cytochrome P-450 metabolism of caffeine. However, a well-conducted pharmacokinetic/pharmacodynamic study did not demonstrate this effect. The clinical significance of this potential interaction is unknown.